title: Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience.
abstract: BACKGROUND
  The data base of the Eastern Cooperative Oncology Group (ECOG) provides access to data on a large adult patient population drawn from more than 25 major university institutions and hundreds of participating hospitals. Extensive medical files are maintained at the ECOG Coordinating Center and are updated regularly.
  
  
  METHODS
  Data on 1414 eligible patients with acute myeloid leukemia (AML), treated on 6 ECOG protocols during the period 1976-1994, were reviewed to determine the number of long-term survivors (LTS) and to identify factors that predicted LTS. Disease free survival and factors impacting quality of life were examined as well.
  
  
  RESULTS
  Of the 1414 patients, 274 survived for > or = 3 years and were considered LTS. A logistic regression analysis revealed that factors predicting LTS included age < 55 years, female gender, treatment between 1985 and 1990, white blood cell count < 10,000 cells/mm3, and hemoglobin > 10 g/dL. Disease free survival improved with escalating intensity of therapy. Quality-of-life data showed that infections were fairly common. Significant graft-versus-host disease occurred in 6 of 40 patients who received allogeneic bone marrow transplantation and contributed to the deaths of 4 individuals. Information on employment, insurance, social or marital difficulties, and psychosocial issues was more difficult to obtain.
  
  
  CONCLUSIONS
  Prognosis in AML is a complex interaction involving the cellular origin of the malignant clone, morphology, and evolving therapeutic strategies. The most recent ECOG studies incorporate these variables and should provide additional insights into factors affecting LTS in patients with AML.
authors.affiliation: Hematology/Medical Oncology Unit, University of Rochester Cancer Center, New York 14642, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Bennett
authors.forename: M L
authors.initials: ML
authors.lastname: Young
authors.forename: J W
authors.initials: JW
authors.lastname: Andersen
authors.forename: P A
authors.initials: PA
authors.lastname: Cassileth
authors.forename: M S
authors.initials: MS
authors.lastname: Tallman
authors.forename: E
authors.initials: E
authors.lastname: Paietta
authors.forename: P H
authors.initials: PH
authors.lastname: Wiernik
authors.forename: J M
authors.initials: JM
authors.lastname: Rowe
mesh_terms: D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011379:Prognosis; D011788:Quality of Life; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome